[S02DA03, antipyrine, The risk or severity of hypertension can be increased when Norepinephrine is combined with Antipyrine.]
[M01AB02, sulindac, The risk or severity of hypertension can be increased when Norepinephrine is combined with Sulindac.]
[M01AX04, apazone, The risk or severity of hypertension can be increased when Norepinephrine is combined with Azapropazone.]
[L01BB02, mercaptopurine, The risk or severity of adverse effects can be increased when Norepinephrine is combined with Mercaptopurine.]
[R03CC03, terbutaline, The therapeutic efficacy of Terbutaline can be increased when used in combination with Norepinephrine.]
[N05AE05, lurasidone, Lurasidone may decrease the hypertensive activities of Norepinephrine.]
[A04AD10, dronabinol, The risk or severity of Tachycardia can be increased when Dronabinol is combined with Norepinephrine.]
[R03DA07, theobromine, The risk or severity of adverse effects can be increased when Norepinephrine is combined with Theobromine.]
[R03DA04, theophylline, The risk or severity of adverse effects can be increased when Norepinephrine is combined with Theophylline.]
[A11DA01, thiamine, The serum concentration of Norepinephrine can be increased when it is combined with Thiamine.]
[R06AD03, thiethylperazine, The therapeutic efficacy of Norepinephrine can be increased when used in combination with Thiethylperazine.]
[N05AB08, thioproperazine, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Thioproperazine.]
[N05AC02, thioridazine, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Thioridazine.]
[G04BE06, moxisylyte, Moxisylyte may decrease the hypertensive activities of Norepinephrine.]
[V04CJ01, thyrotropin, The risk or severity of adverse effects can be increased when Norepinephrine is combined with Thyrotropin.]
[V04CJ02, thyrotropin-releasing hormone, The risk or severity of adverse effects can be increased when Norepinephrine is combined with Protirelin.]
[S01ED01, timolol, Timolol may decrease the bronchodilatory activities of Norepinephrine.]
[M02AX02, tolazoline, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Tolazoline.]
[M02AA21, tolmetin, The risk or severity of hypertension can be increased when Norepinephrine is combined with Tolmetin.]
[N02AX02, tramadol, The risk or severity of Tachycardia can be increased when Tramadol is combined with Norepinephrine.]
[N06AF04, tranylcypromine, Tranylcypromine may increase the hypertensive activities of Norepinephrine.]
[N06AX05, trazodone, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Trazodone.]
[S01BA05, triamcinolone, The risk or severity of hypokalemia can be increased when Triamcinolone is combined with Norepinephrine.]
[C03DB02, triamterene, The risk or severity of Cardiac Arrhythmia can be increased when Norepinephrine is combined with Triamterene.]
[C03AA06, trichlormethiazide, The risk or severity of hypokalemia can be increased when Norepinephrine is combined with Trichlormethiazide.]
[A03AB12, mepenzolate, The risk or severity of Tachycardia can be increased when Norepinephrine is combined with Mepenzolate.]
[N05AB06, trifluoperazine, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Trifluoperazine.]
[N05AA05, triflupromazine, The risk or severity of Tachycardia can be increased when Norepinephrine is combined with Triflupromazine.]
[D07AC02, fluclorolone, The risk or severity of hypokalemia can be increased when Fluclorolone is combined with Norepinephrine.]
[N04AA01, trihexyphenidyl, The risk or severity of Tachycardia can be increased when Norepinephrine is combined with Trihexyphenidyl.]
[R03BA07, mometasone, The risk or severity of hypokalemia can be increased when Mometasone is combined with Norepinephrine.]
[A03AA05, trimebutine, The risk or severity of Tachycardia can be increased when Norepinephrine is combined with Trimebutine.]
[R06AD01, trimeprazine, The therapeutic efficacy of Norepinephrine can be increased when used in combination with Alimemazine.]
[C02BA01, trimethaphan, Norepinephrine may decrease the antihypertensive activities of Trimethaphan.]
[J01EA01, trimethoprim, The serum concentration of Norepinephrine can be increased when it is combined with Trimethoprim.]
[N06AA06, trimipramine, Trimipramine may increase the vasopressor activities of Norepinephrine.]
[R06AC04, tripelennamine, The therapeutic efficacy of Norepinephrine can be increased when used in combination with Tripelennamine.]
[R06AX07, triprolidine, The therapeutic efficacy of Norepinephrine can be increased when used in combination with Triprolidine.]
[A03BB01, butylscopolamine, The risk or severity of Tachycardia can be increased when Norepinephrine is combined with Butylscopolamine.]
[N06AX24, vilazodone, The risk or severity of hypertension can be increased when Norepinephrine is combined with Vilazodone.]
[C09CA09, azilsartan medoxomil, Norepinephrine may decrease the antihypertensive activities of Azilsartan medoxomil.]
[L01EX04, vandetanib, The serum concentration of Norepinephrine can be increased when it is combined with Vandetanib.]
[A10BH05, linagliptin, The serum concentration of Linagliptin can be increased when it is combined with Norepinephrine.]
[R03AC18, indacaterol, The risk or severity of adverse effects can be increased when Norepinephrine is combined with Indacaterol.]
[C08DA01, verapamil, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Verapamil.]
[C04AX07, vincamine, Norepinephrine may decrease the antihypertensive activities of Vincamine.]
[N01AX15, xenon, Xenon may increase the arrhythmogenic activities of Norepinephrine.]
[C03BA10, xipamide, The risk or severity of Cardiac Arrhythmia can be increased when Norepinephrine is combined with Xipamide.]
[N05AF05, zuclopenthixol, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Zuclopenthixol.]
[J05AE02, indinavir, The risk or severity of adverse effects can be increased when Indinavir is combined with Norepinephrine.]
[L01ED01, crizotinib, The serum concentration of Norepinephrine can be increased when it is combined with Crizotinib.]
[N05AE04, ziprasidone, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Ziprasidone.]
[G03AC10, drospirenone, The risk or severity of Cardiac Arrhythmia can be increased when Norepinephrine is combined with Drospirenone.]
[N02BA01, aspirin, The risk or severity of hypertension can be increased when Norepinephrine is combined with Acetylsalicylic acid.]
[G04BD07, tolterodine, The risk or severity of Tachycardia can be increased when Norepinephrine is combined with Tolterodine.]
[C07AB03, atenolol, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Atenolol.]
[S01FA01, atropine, The risk or severity of hypertension can be increased when Norepinephrine is combined with Atropine.]
[H02AB11, prednylidene, The risk or severity of hypokalemia can be increased when Prednylidene is combined with Norepinephrine.]
[G04BD12, mirabegron, The risk or severity of hypertension can be increased when Norepinephrine is combined with Mirabegron.]
[C01CA18, octopamine, The risk or severity of hypertension can be increased when Norepinephrine is combined with Octopamine.]
[H02AA01, aldosterone, The risk or severity of hypokalemia can be increased when Aldosterone is combined with Norepinephrine.]
[C01AA01, acetyldigitoxin, The risk or severity of Cardiac Arrhythmia can be increased when Norepinephrine is combined with Acetyldigitoxin.]
[J05AE04, nelfinavir, The risk or severity of adverse effects can be increased when Nelfinavir is combined with Norepinephrine.]
[N04BD02, rasagiline, Rasagiline may increase the hypertensive activities of Norepinephrine.]
[C08CA13, lercanidipine, Norepinephrine may decrease the antihypertensive activities of Lercanidipine.]
[N02CC03, zolmitriptan, The risk or severity of hypertension can be increased when Zolmitriptan is combined with Norepinephrine.]
[R06AC06, thonzylamine, The therapeutic efficacy of Norepinephrine can be increased when used in combination with Thonzylamine.]
[G04BD10, darifenacin, The risk or severity of Tachycardia can be increased when Norepinephrine is combined with Darifenacin.]
[N01AA01, ethyl ether, Diethyl ether may increase the arrhythmogenic activities of Norepinephrine.]
[C03AA01, bendroflumethiazide, The risk or severity of hypokalemia can be increased when Norepinephrine is combined with Bendroflumethiazide.]
[N02BA10, benorilate, The risk or severity of hypertension can be increased when Norepinephrine is combined with Benorilate.]
[A10BK02, canagliflozin, The risk or severity of Cardiac Arrhythmia can be increased when Norepinephrine is combined with Canagliflozin.]
[H03AA04, tiratricol, The risk or severity of adverse effects can be increased when Norepinephrine is combined with Tiratricol.]
[M01AH01, celecoxib, The risk or severity of hypertension can be increased when Norepinephrine is combined with Celecoxib.]
[N02CC02, naratriptan, The risk or severity of hypertension can be increased when Norepinephrine is combined with Naratriptan.]
[N04AC01, benztropine, The risk or severity of Tachycardia can be increased when Benzatropine is combined with Norepinephrine.]
[L01EC02, dabrafenib, The serum concentration of Norepinephrine can be increased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, The risk or severity of hypertension can be increased when Norepinephrine is combined with Benzydamine.]
[H05AA03, parathyroid hormone, The risk or severity of adverse effects can be increased when Norepinephrine is combined with Parathyroid hormone.]
[N06AX28, levomilnacipran, Levomilnacipran may increase the tachycardic activities of Norepinephrine.]
[J05AJ03, dolutegravir, The serum concentration of Norepinephrine can be increased when it is combined with Dolutegravir.]
[C08EA02, bepridil, Norepinephrine may decrease the antihypertensive activities of Bepridil.]
[C02KX05, riociguat, Norepinephrine may decrease the antihypertensive activities of Riociguat.]
[C02KX04, macitentan, Norepinephrine may decrease the antihypertensive activities of Macitentan.]
[N06AX26, vortioxetine, The risk or severity of hypertension can be increased when Norepinephrine is combined with Vortioxetine.]
[A10BK01, dapagliflozin, The risk or severity of Cardiac Arrhythmia can be increased when Norepinephrine is combined with Dapagliflozin.]
[C01CA27, droxidopa, The therapeutic efficacy of Norepinephrine can be increased when used in combination with Droxidopa.]
[C07AB04, acebutolol, The therapeutic efficacy of Acebutolol can be increased when used in combination with Norepinephrine.]
[N07CA01, betahistine, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Betahistine.]
[S03BA03, betamethasone, The risk or severity of hypokalemia can be increased when Betamethasone is combined with Norepinephrine.]
[S01ED02, betaxolol, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Betaxolol.]
[C02CC01, bethanidine, Norepinephrine may decrease the antihypertensive activities of Bethanidine.]
[A03BA03, hyoscyamine, The risk or severity of Tachycardia can be increased when Norepinephrine is combined with Hyoscyamine.]
[R03AC19, olodaterol, The risk or severity of adverse effects can be increased when Norepinephrine is combined with Olodaterol.]
[D11AA01, glycopyrronium, The risk or severity of Tachycardia can be increased when Norepinephrine is combined with Glycopyrronium.]
[N05AA04, acepromazine, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Acepromazine.]
[V04CX03, methacholine, Norepinephrine may decrease effectiveness of Methacholine as a diagnostic agent.]
[N04AA02, biperiden, The risk or severity of Tachycardia can be increased when Norepinephrine is combined with Biperiden.]
[S03AA06, gentamicin, The serum concentration of Gentamicin can be increased when it is combined with Norepinephrine.]
[N06AX11, mirtazapine, Mirtazapine may decrease the antihypertensive activities of Norepinephrine.]
[L01EF01, palbociclib, The risk or severity of adverse effects can be increased when Palbociclib is combined with Norepinephrine.]
[L01EX08, lenvatinib, The serum concentration of Norepinephrine can be increased when it is combined with Lenvatinib.]
[A03AA09, difemerine, The risk or severity of Tachycardia can be increased when Norepinephrine is combined with Difemerine.]
[N05AX16, brexpiprazole, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Brexpiprazole.]
[G02CX02, flibanserin, The risk or severity of hypertension can be increased when Norepinephrine is combined with Flibanserin.]
[N05AX15, cariprazine, The risk or severity of hypertension can be increased when Norepinephrine is combined with Cariprazine.]
[M02AA25, aceclofenac, The risk or severity of hypertension can be increased when Norepinephrine is combined with Aceclofenac.]
[M01AB11, acemetacin, The risk or severity of hypertension can be increased when Norepinephrine is combined with Acemetacin.]
[S01EC01, acetazolamide, The risk or severity of Cardiac Arrhythmia can be increased when Norepinephrine is combined with Acetazolamide.]
[J02AC05, isavuconazole, The serum concentration of Norepinephrine can be increased when it is combined with Isavuconazole.]
[B01AC27, selexipag, Norepinephrine may decrease the antihypertensive activities of Selexipag.]
[G04CA01, alfuzosin, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Alfuzosin.]
[M01AE16, alminoprofen, The risk or severity of hypertension can be increased when Norepinephrine is combined with Alminoprofen.]
[N04BC01, bromocriptine, Bromocriptine may increase the hypertensive and vasoconstricting activities of Norepinephrine.]
[R06AB01, brompheniramine, The therapeutic efficacy of Norepinephrine can be increased when used in combination with Dexbrompheniramine.]
[N06AA19, amineptin, Amineptine may increase the vasopressor activities of Norepinephrine.]
[C08CA01, amlodipine, Norepinephrine may decrease the antihypertensive activities of Amlodipine.]
[C03CA02, bumetanide, The risk or severity of hypokalemia can be increased when Norepinephrine is combined with Bumetanide.]
[C07AA19, bupranolol, Bupranolol may decrease the bronchodilatory activities of Norepinephrine.]
[N05BE01, buspirone, The risk or severity of hypertension can be increased when Norepinephrine is combined with Buspirone.]
[R06AX09, azatadine, The therapeutic efficacy of Norepinephrine can be increased when used in combination with Azatadine.]
[S01GX07, azelastine, The therapeutic efficacy of Norepinephrine can be increased when used in combination with Azelastine.]
[A07EC04, balsalazide, The risk or severity of hypertension can be increased when Norepinephrine is combined with Balsalazide.]
[R03CC12, bambuterol, The risk or severity of adverse effects can be increased when Norepinephrine is combined with Bambuterol.]
[R03DA08, bamifylline, The risk or severity of adverse effects can be increased when Norepinephrine is combined with Bamifylline.]
[N06BC01, caffeine, The risk or severity of adverse effects can be increased when Norepinephrine is combined with Caffeine.]
[C09AA07, benazepril, Norepinephrine may decrease the antihypertensive activities of Benazepril.]
[J01XX08, linezolid, The risk or severity of hypertension can be increased when Linezolid is combined with Norepinephrine.]
[H03BA03, benzylthiouracil, The risk or severity of adverse effects can be increased when Norepinephrine is combined with Benzylthiouracil.]
[H05AA04, abaloparatide, The risk or severity of adverse effects can be increased when Norepinephrine is combined with Abaloparatide.]
[N04BD03, safinamide, Safinamide may increase the hypertensive activities of Norepinephrine.]
[L01XX59, enasidenib, The serum concentration of Norepinephrine can be increased when it is combined with Enasidenib.]
[C07AB07, bisoprolol, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Bisoprolol.]
[R03AC17, bitolterol, The risk or severity of adverse effects can be increased when Norepinephrine is combined with Bitolterol.]
[J05AG03, efavirenz, The risk or severity of adverse effects can be increased when Efavirenz is combined with Norepinephrine.]
[C07AA17, bopindolol, Bopindolol may decrease the bronchodilatory activities of Norepinephrine.]
[N04AA11, bornaprine, The risk or severity of Tachycardia can be increased when Norepinephrine is combined with Bornaprine.]
[C03DA03, canrenone, The risk or severity of Cardiac Arrhythmia can be increased when Norepinephrine is combined with Canrenone.]
[R03BA02, budesonide, The risk or severity of hypokalemia can be increased when Budesonide is combined with Norepinephrine.]
[C04AX20, buflomedil, Buflomedil may decrease the hypertensive activities of Norepinephrine.]
[M01AB07, bumadizone, The risk or severity of hypertension can be increased when Norepinephrine is combined with Bumadizone.]
[N06AA15, butriptyline, Butriptyline may increase the vasopressor activities of Norepinephrine.]
[C01AA02, acetyldigoxins, The risk or severity of Cardiac Arrhythmia can be increased when Norepinephrine is combined with Acetyldigoxin.]
[A10BK04, ertugliflozin, The risk or severity of Cardiac Arrhythmia can be increased when Norepinephrine is combined with Ertugliflozin.]
[R06AX18, acrivastine, The therapeutic efficacy of Norepinephrine can be increased when used in combination with Acrivastine.]
[C09AA01, captopril, Norepinephrine may decrease the antihypertensive activities of Captopril.]
[L02BB05, apalutamide, The serum concentration of Norepinephrine can be increased when it is combined with Apalutamide.]
[A03AA03, camylofine, The risk or severity of Tachycardia can be increased when Norepinephrine is combined with Camylofin.]
[H03BB01, carbimazole, The risk or severity of adverse effects can be increased when Norepinephrine is combined with Carbimazole.]
[R06AA08, carbinoxamine, The therapeutic efficacy of Norepinephrine can be increased when used in combination with Carbinoxamine.]
[C07AG02, carvedilol, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Carvedilol.]
[N03AX24, cannabidiol, The risk or severity of hypertension can be increased when Norepinephrine is combined with Cannabidiol.]
[C07AB08, celiprolol, The therapeutic efficacy of Celiprolol can be increased when used in combination with Norepinephrine.]
[P01BA07, tafenoquine, The serum concentration of Norepinephrine can be increased when it is combined with Tafenoquine.]
[L01EB07, dacomitinib, The risk or severity of adverse effects can be increased when Dacomitinib is combined with Norepinephrine.]
[S01GX12, cetirizine, The therapeutic efficacy of Norepinephrine can be increased when used in combination with Cetirizine.]
[N01BA04, chloroprocaine, The risk or severity of adverse effects can be increased when Norepinephrine is combined with Chloroprocaine.]
[R06AC03, chloropyramine, The therapeutic efficacy of Norepinephrine can be increased when used in combination with Chloropyramine.]
[R06AA06, chlorphenoxamine, The therapeutic efficacy of Norepinephrine can be increased when used in combination with Chlorphenoxamine.]
[M01AC05, lornoxicam, The risk or severity of hypertension can be increased when Norepinephrine is combined with Lornoxicam.]
[R03DA02, oxtriphylline, The risk or severity of adverse effects can be increased when Norepinephrine is combined with Oxtriphylline.]
[L01EX13, gilteritinib, The risk or severity of adverse effects can be increased when Gilteritinib is combined with Norepinephrine.]
[C09AA08, cilazapril, Norepinephrine may decrease the antihypertensive activities of Cilazapril.]
[B01AC23, cilostazol, The risk or severity of Tachycardia can be increased when Norepinephrine is combined with Cilostazol.]
[A03FA08, cinitapride, The risk or severity of hypertension can be increased when Norepinephrine is combined with Cinitapride.]
[N06AX27, esketamine, The risk or severity of hypertension can be increased when Esketamine is combined with Norepinephrine.]
[L04AA42, siponimod, The risk or severity of hypertension can be increased when Norepinephrine is combined with Siponimod.]
[N06BA14, solriamfetol, The risk or severity of hypertension can be increased when Solriamfetol is combined with Norepinephrine.]
[L01EN01, erdafitinib, The serum concentration of Norepinephrine can be increased when it is combined with Erdafitinib.]
[H02AB14, cloprednol, The risk or severity of hypokalemia can be increased when Cloprednol is combined with Norepinephrine.]
[C09CA06, candesartan, Norepinephrine may decrease the antihypertensive activities of Candesartan.]
[H02AB17, cortivazol, The risk or severity of hypokalemia can be increased when Cortivazol is combined with Norepinephrine.]
[C03BX03, cicletanine, The risk or severity of Cardiac Arrhythmia can be increased when Norepinephrine is combined with Cicletanine.]
[N07XX11, pitolisant, The risk or severity of adverse effects can be increased when Pitolisant is combined with Norepinephrine.]
[C03AA09, cyclothiazide, The risk or severity of hypokalemia can be increased when Norepinephrine is combined with Cyclothiazide.]
[G04BE04, yohimbine, Yohimbine may decrease the hypertensive activities of Norepinephrine.]
[H02AB13, deflazacort, The risk or severity of hypokalemia can be increased when Deflazacort is combined with Norepinephrine.]
[R06AB06, dexbrompheniramine, The therapeutic efficacy of Norepinephrine can be increased when used in combination with Dexbrompheniramine.]
[R06AB02, dexchlorpheniramine, The therapeutic efficacy of Norepinephrine can be increased when used in combination with Dexchlorpheniramine.]
[N02CC07, frovatriptan, The risk or severity of hypertension can be increased when Norepinephrine is combined with Frovatriptan.]
[G04CB02, dutasteride, Dutasteride may decrease the hypertensive activities of Norepinephrine.]
[N02CC06, eletriptan, The risk or severity of hypertension can be increased when Eletriptan is combined with Norepinephrine.]
[M01AH02, rofecoxib, The risk or severity of hypertension can be increased when Norepinephrine is combined with Rofecoxib.]
[C01BD07, dronedarone, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Dronedarone.]
[R06AA07, diphenylpyraline, The therapeutic efficacy of Norepinephrine can be increased when used in combination with Diphenylpyraline.]
[R06AE04, chlorcyclizine, The therapeutic efficacy of Norepinephrine can be increased when used in combination with Chlorcyclizine.]
[C02AA06, methoserpidine, Norepinephrine may decrease the antihypertensive activities of Methoserpidine.]
[L01EH03, tucatinib, The serum concentration of Norepinephrine can be increased when it is combined with Tucatinib.]
[A03AA08, dihexyverine, The risk or severity of Tachycardia can be increased when Norepinephrine is combined with Dihexyverine.]
[N04BX04, opicapone, The metabolism of Norepinephrine can be decreased when combined with Opicapone.]
[C01CA14, dopexamine, The risk or severity of hypertension can be increased when Norepinephrine is combined with Dopexamine.]
[D07XB03, fluprednidene, The risk or severity of hypokalemia can be increased when Fluprednidene is combined with Norepinephrine.]
[G04BD09, trospium, The risk or severity of Tachycardia can be increased when Trospium is combined with Norepinephrine.]
[M01AC04, droxicam, The risk or severity of hypertension can be increased when Norepinephrine is combined with Droxicam.]
[L01EX22, selpercatinib, The risk or severity of hypertension can be increased when Norepinephrine is combined with Selpercatinib.]
[M02AA27, dexketoprofen, The risk or severity of hypertension can be increased when Norepinephrine is combined with Dexketoprofen.]
[C08CA17, levamlodipine, Norepinephrine may decrease the antihypertensive activities of Levamlodipine.]
[R06AX22, ebastine, The therapeutic efficacy of Norepinephrine can be increased when used in combination with Ebastine.]
[C03AA04, chlorothiazide, The risk or severity of hypokalemia can be increased when Norepinephrine is combined with Chlorothiazide.]
[R06AB04, chlorpheniramine, The serum concentration of Norepinephrine can be increased when it is combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Chlorpromazine.]
[N05AF03, chlorprothixene, The risk or severity of Tachycardia can be increased when Norepinephrine is combined with Chlorprothixene.]
[C03BA04, chlorthalidone, The risk or severity of Cardiac Arrhythmia can be increased when Norepinephrine is combined with Chlorthalidone.]
[N02BA07, ethenzamide, The risk or severity of hypertension can be increased when Norepinephrine is combined with Ethenzamide.]
[N02BA03, choline salicylate, The serum concentration of Choline salicylate can be increased when it is combined with Norepinephrine.]
[M01AB08, etodolac, The risk or severity of hypertension can be increased when Norepinephrine is combined with Etodolac.]
[M02AA06, etofenamate, The risk or severity of hypertension can be increased when Norepinephrine is combined with Etofenamate.]
[L01FX21, naxitamab, The risk or severity of hypertension can be increased when Norepinephrine is combined with Naxitamab.]
[V03AF12, trilaciclib, The serum concentration of Norepinephrine can be increased when it is combined with Trilaciclib.]
[M01AE05, fenbufen, The risk or severity of hypertension can be increased when Norepinephrine is combined with Fenbufen.]
[N06BA10, fenethylline, The risk or severity of adverse effects can be increased when Norepinephrine is combined with Fenethylline.]
[C01CA19, fenoldopam, Norepinephrine may decrease the antihypertensive activities of Fenoldopam.]
[N06BA08, fenozolone, The therapeutic efficacy of Fenozolone can be increased when used in combination with Norepinephrine.]
[G04CB01, finasteride, The risk or severity of hypertension can be increased when Norepinephrine is combined with Finasteride.]
[R03BA03, flunisolide, The risk or severity of hypokalemia can be increased when Flunisolide is combined with Norepinephrine.]
[S02BA08, fluocinolone acetonide, The risk or severity of hypokalemia can be increased when Fluocinolone acetonide is combined with Norepinephrine.]
[R03CC15, formoterol, Norepinephrine may increase the sympathomimetic activities of Formoterol.]
[N01AB05, trichloroethylene, Trichloroethylene may increase the arrhythmogenic activities of Norepinephrine.]
[H04AA02, dasiglucagon, Norepinephrine may decrease the antihypertensive activities of Dasiglucagon.]
[G03GA06, follitropin beta, The risk or severity of adverse effects can be increased when Norepinephrine is combined with Follitropin.]
[A02BA01, cimetidine, The serum concentration of Cimetidine can be increased when it is combined with Norepinephrine.]
[L01XA01, cisplatin, The serum concentration of Cisplatin can be increased when it is combined with Norepinephrine.]
[C03DA05, finerenone, The risk or severity of Cardiac Arrhythmia can be increased when Norepinephrine is combined with Finerenone.]
[P01CA03, fexinidazole, The serum concentration of Norepinephrine can be increased when it is combined with Fexinidazole.]
[V09AB03, ioflupane I-123, Norepinephrine may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.]
[R06AA04, clemastine, The therapeutic efficacy of Norepinephrine can be increased when used in combination with Clemastine.]
[M01AG01, mefenamic acid, The risk or severity of hypertension can be increased when Norepinephrine is combined with Mefenamic acid.]
[R03CC13, clenbuterol, The therapeutic efficacy of Clenbuterol can be increased when used in combination with Norepinephrine.]
[L01EJ03, pacritinib, The serum concentration of Norepinephrine can be increased when it is combined with Pacritinib.]
[N06AA04, clomipramine, Clomipramine may increase the vasopressor activities of Norepinephrine.]
[S01EA04, clonidine, Norepinephrine may decrease the antihypertensive activities of Clonidine.]
[C03BA03, clopamide, The risk or severity of Cardiac Arrhythmia can be increased when Norepinephrine is combined with Clopamide.]
[N05AH02, clozapine, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Clozapine.]
[S02DA02, cocaine, The risk or severity of Tachycardia can be increased when Norepinephrine is combined with Cocaine.]
[C02KB01, metyrosine, Norepinephrine may decrease the antihypertensive activities of Metyrosine.]
[M01AX13, proquazone, The risk or severity of hypertension can be increased when Norepinephrine is combined with Proquazone.]
[R05DA04, codeine, The risk or severity of adverse effects can be increased when Codeine is combined with Norepinephrine.]
[A03AB10, hexocyclium, The risk or severity of Tachycardia can be increased when Norepinephrine is combined with Hexocyclium.]
[A03BB06, homatropine methylbromide, The risk or severity of Tachycardia can be increased when Norepinephrine is combined with Homatropine methylbromide.]
[N01AB07, desflurane, Desflurane may increase the arrhythmogenic activities of Norepinephrine.]
[C04AX28, ifenprodil, Ifenprodil may decrease the hypertensive activities of Norepinephrine.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of hypertension can be increased when Norepinephrine is combined with Imidazole salicylate.]
[R03BA08, ciclesonide, The risk or severity of hypokalemia can be increased when Ciclesonide is combined with Norepinephrine.]
[B01AC10, indobufen, The risk or severity of hypertension can be increased when Norepinephrine is combined with Indobufen.]
[R06AX27, desloratadine, The therapeutic efficacy of Norepinephrine can be increased when used in combination with Desloratadine.]
[M01AH03, valdecoxib, The risk or severity of hypertension can be increased when Norepinephrine is combined with Valdecoxib.]
[C01AA06, lanatoside C, The risk or severity of Cardiac Arrhythmia can be increased when Norepinephrine is combined with Lanatoside C.]
[A03AX10, isometheptene, The risk or severity of hypertension can be increased when Norepinephrine is combined with Isometheptene.]
[N02CC05, almotriptan, The risk or severity of hypertension can be increased when Norepinephrine is combined with Almotriptan.]
[M01AH04, parecoxib, The risk or severity of hypertension can be increased when Norepinephrine is combined with Parecoxib.]
[R06AD09, isothipendyl, The therapeutic efficacy of Norepinephrine can be increased when used in combination with Isothipendyl.]
[S01AD03, acyclovir, The risk or severity of adverse effects can be increased when Acyclovir is combined with Norepinephrine.]
[M01AA06, kebuzone, The risk or severity of hypertension can be increased when Norepinephrine is combined with Kebuzone.]
[L01EA01, imatinib, The serum concentration of Norepinephrine can be increased when it is combined with Imatinib.]
[C08CA09, lacidipine, Norepinephrine may decrease the antihypertensive activities of Lacidipine.]
[N03AX09, lamotrigine, The serum concentration of Norepinephrine can be increased when it is combined with Lamotrigine.]
[S01BA03, cortisone, The risk or severity of hypokalemia can be increased when Cortisone is combined with Norepinephrine.]
[N07BC04, lofexidine, Norepinephrine may decrease the antihypertensive activities of Lofexidine.]
[M01AB09, lonazolac, The risk or severity of hypertension can be increased when Norepinephrine is combined with Lonazolac.]
[R06AX13, loratadine, The therapeutic efficacy of Norepinephrine can be increased when used in combination with Loratadine.]
[M02AA31, loxoprofen, The risk or severity of hypertension can be increased when Norepinephrine is combined with Loxoprofen.]
[C09AA03, lisinopril, Norepinephrine may decrease the antihypertensive activities of Lisinopril.]
[C08CA11, manidipine, Norepinephrine may decrease the antihypertensive activities of Manidipine.]
[A03AA04, mebeverine, The risk or severity of Tachycardia can be increased when Norepinephrine is combined with Mebeverine.]
[R06AX15, mebhydroline, The therapeutic efficacy of Norepinephrine can be increased when used in combination with Mebhydrolin.]
[A08AA09, mefenorex, The therapeutic efficacy of Mefenorex can be increased when used in combination with Norepinephrine.]
[C07AA14, mepindolol, Mepindolol may decrease the bronchodilatory activities of Norepinephrine.]
[H02AB15, meprednisone, The risk or severity of hypokalemia can be increased when Meprednisone is combined with Norepinephrine.]
[R06AD07, mequitazine, The therapeutic efficacy of Norepinephrine can be increased when used in combination with Mequitazine.]
[C01EB10, adenosine, The risk or severity of Tachycardia can be increased when Norepinephrine is combined with Adenosine.]
[R06AD04, methdilazine, The therapeutic efficacy of Norepinephrine can be increased when used in combination with Methdilazine.]
[N04AA03, methixene, The risk or severity of Tachycardia can be increased when Metixene is combined with Norepinephrine.]
[R03CB02, methoxyphenamine, The therapeutic efficacy of Methoxyphenamine can be increased when used in combination with Norepinephrine.]
[R06AE03, cyclizine, The therapeutic efficacy of Norepinephrine can be increased when used in combination with Cyclizine.]
[C03DA04, eplerenone, The risk or severity of Cardiac Arrhythmia can be increased when Norepinephrine is combined with Eplerenone.]
[C03AA07, cyclopenthiazide, The risk or severity of hypokalemia can be increased when Norepinephrine is combined with Cyclopenthiazide.]
[N06AX07, minaprine, Minaprine may increase the hypertensive activities of Norepinephrine.]
[S01XA18, cyclosporine, The risk or severity of hypertension can be increased when Cyclosporine is combined with Norepinephrine.]
[N06AG02, moclobemide, Moclobemide may increase the hypertensive activities of Norepinephrine.]
[R06AX02, cyproheptadine, The therapeutic efficacy of Norepinephrine can be increased when used in combination with Cyproheptadine.]
[C09AA13, moexipril, Norepinephrine may decrease the antihypertensive activities of Moexipril.]
[M02AA02, mofebutazone, The risk or severity of hypertension can be increased when Norepinephrine is combined with Mofebutazone.]
[M01AX22, morniflumate, The risk or severity of hypertension can be increased when Norepinephrine is combined with Morniflumate.]
[C03XA02, conivaptan, The risk or severity of Cardiac Arrhythmia can be increased when Norepinephrine is combined with Conivaptan.]
[C02AC05, moxonidine, Norepinephrine may decrease the antihypertensive activities of Moxonidine.]
[M01AH05, etoricoxib, The risk or severity of hypertension can be increased when Norepinephrine is combined with Etoricoxib.]
[C02CC04, debrisoquin, Norepinephrine may decrease the antihypertensive activities of Debrisoquine.]
[A04AD11, nabilone, The risk or severity of Tachycardia can be increased when Nabilone is combined with Norepinephrine.]
[M01AX01, nabumetone, The risk or severity of hypertension can be increased when Norepinephrine is combined with Nabumetone.]
[C07AB12, nebivolol, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Nebivolol.]
[N06AX06, nefazodone, Nefazodone may increase the tachycardic activities of Norepinephrine.]
[C01DX16, nicorandil, Norepinephrine may decrease the antihypertensive activities of Nicorandil.]
[C01CA23, theodrenaline, The therapeutic efficacy of Norepinephrine can be increased when used in combination with Theodrenaline.]
[C01CA05, norfenefrine, The risk or severity of hypertension can be increased when Norepinephrine is combined with Norfenefrine.]
[G04BD08, solifenacin, The risk or severity of hypertension can be increased when Norepinephrine is combined with Solifenacin.]
[A07EC03, olsalazine, The risk or severity of hypertension can be increased when Norepinephrine is combined with Olsalazine.]
[N06AA01, desipramine, Desipramine may increase the vasopressor activities of Norepinephrine.]
[C01AA07, deslanoside, The risk or severity of Cardiac Arrhythmia can be increased when Norepinephrine is combined with Deslanoside.]
[H01BA02, desmopressin, The risk or severity of hypertension can be increased when Desmopressin is combined with Norepinephrine.]
[D07XC02, desoximetasone, The risk or severity of hypokalemia can be increased when Desoximetasone is combined with Norepinephrine.]
[H02AA03, desoxycorticosterone, The risk or severity of hypokalemia can be increased when Desoxycortone is combined with Norepinephrine.]
[C09XA02, aliskiren, Norepinephrine may decrease the antihypertensive activities of Aliskiren.]
[L01XA03, oxaliplatin, The serum concentration of Oxaliplatin can be increased when it is combined with Norepinephrine.]
[M01AE12, oxaprozin, The risk or severity of hypertension can be increased when Norepinephrine is combined with Oxaprozin.]
[S03BA01, dexamethasone, The risk or severity of hypokalemia can be increased when Dexamethasone is combined with Norepinephrine.]
[N04AA08, dexetimide, The risk or severity of Tachycardia can be increased when Norepinephrine is combined with Dexetimide.]
[G04BD04, oxybutynin, The risk or severity of Tachycardia can be increased when Norepinephrine is combined with Oxybutynin.]
[A03AA01, oxyphencyclimine, The risk or severity of Tachycardia can be increased when Norepinephrine is combined with Oxyphencyclimine.]
[N06BA02, dextroamphetamine, The therapeutic efficacy of Amphetamine can be increased when used in combination with Norepinephrine.]
[H05AA02, teriparatide, The risk or severity of adverse effects can be increased when Norepinephrine is combined with Teriparatide.]
[N06AB05, paroxetine, The risk or severity of Tachycardia can be increased when Norepinephrine is combined with Paroxetine.]
[B01AC04, clopidogrel, The serum concentration of Norepinephrine can be increased when it is combined with Clopidogrel.]
[C04AD01, pentifylline, The risk or severity of adverse effects can be increased when Norepinephrine is combined with Pentifylline.]
[V03AH01, diazoxide, Norepinephrine may decrease the antihypertensive activities of Diazoxide.]
[R06AX04, phenindamine, The therapeutic efficacy of Norepinephrine can be increased when used in combination with Phenindamine.]
[N06AA08, dibenzepin, Dibenzepin may increase the vasopressor activities of Norepinephrine.]
[S01EC02, dichlorphenamide, The risk or severity of Cardiac Arrhythmia can be increased when Norepinephrine is combined with Diclofenamide.]
[S01BC03, diclofenac, The risk or severity of hypertension can be increased when Norepinephrine is combined with Diclofenac.]
[A03AA07, dicyclomine, The risk or severity of Tachycardia can be increased when Norepinephrine is combined with Dicyclomine.]
[R06AX23, pimethixene, The therapeutic efficacy of Norepinephrine can be increased when used in combination with Pimethixene.]
[C02DG01, pinacidil, Norepinephrine may decrease the antihypertensive activities of Pinacidil.]
[A03AB14, pipenzolate, The risk or severity of Tachycardia can be increased when Norepinephrine is combined with Pipenzolate.]
[R03CC07, pirbuterol, The risk or severity of adverse effects can be increased when Norepinephrine is combined with Pirbuterol.]
[C03CA03, piretanide, The risk or severity of hypokalemia can be increased when Norepinephrine is combined with Piretanide.]
[A08AA03, diethylpropion, The therapeutic efficacy of Diethylpropion can be increased when used in combination with Norepinephrine.]
[C08CA03, isradipine, Norepinephrine may decrease the antihypertensive activities of Isradipine.]
[D07XC04, diflucortolone, The risk or severity of hypokalemia can be increased when Difluocortolone is combined with Norepinephrine.]
[A03AB11, poldine, The risk or severity of Tachycardia can be increased when Norepinephrine is combined with Poldine.]
[N02BA11, diflunisal, The risk or severity of hypertension can be increased when Norepinephrine is combined with Diflunisal.]
[C01AA04, digitoxin, The risk or severity of Cardiac Arrhythmia can be increased when Norepinephrine is combined with Digitoxin.]
[C01AA05, digoxin, The risk or severity of Cardiac Arrhythmia can be increased when Norepinephrine is combined with Digoxin.]
[C02DB01, dihydralazine, Norepinephrine may decrease the antihypertensive activities of Dihydralazine.]
[C04AE04, dihydroergocristine, Dihydroergocristine may increase the hypertensive and vasoconstricting activities of Norepinephrine.]
[N02CA01, dihydroergotamine, Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Norepinephrine.]
[B01AC21, treprostinil, Norepinephrine may decrease the antihypertensive activities of Treprostinil.]
[H03BC01, potassium perchlorate, The risk or severity of adverse effects can be increased when Norepinephrine is combined with Potassium perchlorate.]
[C08DB01, diltiazem, Norepinephrine may decrease the antihypertensive activities of Diltiazem.]
[R06AA11, dimenhydrinate, The therapeutic efficacy of Norepinephrine can be increased when used in combination with Dimenhydrinate.]
[R06AB03, dimethindene, The therapeutic efficacy of Norepinephrine can be increased when used in combination with Dimetindene.]
[R03CC08, procaterol, The therapeutic efficacy of Procaterol can be increased when used in combination with Norepinephrine.]
[N06BC02, propentofylline, The risk or severity of adverse effects can be increased when Norepinephrine is combined with Propentofylline.]
[N02BB04, propyphenazone, The risk or severity of hypertension can be increased when Norepinephrine is combined with Propyphenazone.]
[M01AB14, proglumetacin, The risk or severity of hypertension can be increased when Norepinephrine is combined with Proglumetacin.]
[G02AD02, dinoprostone, The serum concentration of Norepinephrine can be increased when it is combined with Dinoprostone.]
[R03DA03, proxyphylline, The risk or severity of adverse effects can be increased when Norepinephrine is combined with Proxyphylline.]
[R06AA02, diphenhydramine, The serum concentration of Norepinephrine can be increased when it is combined with Diphenhydramine.]
[C09AA06, quinapril, Norepinephrine may decrease the antihypertensive activities of Quinapril.]
[N06BA11, dexmethylphenidate, The risk or severity of hypertension can be increased when Norepinephrine is combined with Dexmethylphenidate.]
[N06AA23, quinupramine, Quinupramine may increase the vasopressor activities of Norepinephrine.]
[C09AA05, ramipril, Norepinephrine may decrease the antihypertensive activities of Ramipril.]
[R03CC14, reproterol, The risk or severity of hypertension can be increased when Norepinephrine is combined with Reproterol.]
[C01BA03, disopyramide, The serum concentration of Norepinephrine can be increased when it is combined with Disopyramide.]
[N05AX08, risperidone, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Risperidone.]
[R06AE09, levocetirizine, The therapeutic efficacy of Norepinephrine can be increased when used in combination with Levocetirizine.]
[C03XA01, tolvaptan, The risk or severity of Cardiac Arrhythmia can be increased when Norepinephrine is combined with Tolvaptan.]
[G04BE08, tadalafil, Norepinephrine may decrease the antihypertensive activities of Tadalafil.]
[S01BC05, ketorolac, The risk or severity of hypertension can be increased when Norepinephrine is combined with Ketorolac.]
[C02KX02, ambrisentan, Norepinephrine may decrease the antihypertensive activities of Ambrisentan.]
[C01EB18, ranolazine, The serum concentration of Norepinephrine can be increased when it is combined with Ranolazine.]
[N02BA06, salsalate, The risk or severity of hypertension can be increased when Norepinephrine is combined with Salsalate.]
[R03AC12, salmeterol, The risk or severity of adverse effects can be increased when Norepinephrine is combined with Salmeterol.]
[H05BA01, salmon calcitonin, The risk or severity of adverse effects can be increased when Norepinephrine is combined with Salmon calcitonin.]
[C01CA07, dobutamine, The therapeutic efficacy of Dobutamine can be increased when used in combination with Norepinephrine.]
[C01CA04, dopamine, The therapeutic efficacy of Dopamine can be increased when used in combination with Norepinephrine.]
[N06AA16, dothiepin, Dosulepin may increase the vasopressor activities of Norepinephrine.]
[R07AB01, doxapram, The risk or severity of hypertension can be increased when Norepinephrine is combined with Doxapram.]
[N06AA12, doxepin, Doxepin may increase the vasopressor activities of Norepinephrine.]
[R06AA09, doxylamine, The therapeutic efficacy of Norepinephrine can be increased when used in combination with Doxylamine.]
[N01AB08, sevoflurane, Sevoflurane may increase the arrhythmogenic activities of Norepinephrine.]
[N05AD08, droperidol, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Droperidol.]
[A08AA10, sibutramine, Sibutramine may increase the tachycardic activities of Norepinephrine.]
[C09AA11, spirapril, Norepinephrine may decrease the antihypertensive activities of Spirapril.]
[R03DA01, dyphylline, The risk or severity of adverse effects can be increased when Norepinephrine is combined with Dyphylline.]
[N02CC01, sumatriptan, The risk or severity of hypertension can be increased when Norepinephrine is combined with Sumatriptan.]
[C07AB13, talinolol, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Talinolol.]
[H01AA01, corticotropin, The risk or severity of hypokalemia can be increased when Corticotropin is combined with Norepinephrine.]
[M01AC02, tenoxicam, The risk or severity of hypertension can be increased when Norepinephrine is combined with Tenoxicam.]
[G04CA03, terazosin, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Terazosin.]
[C07AA16, tertatolol, Tertatolol may decrease the bronchodilatory activities of Norepinephrine.]
[S01GA02, tetrahydrozoline, The therapeutic efficacy of Tetryzoline can be increased when used in combination with Norepinephrine.]
[G04BD01, emepronium, The risk or severity of Tachycardia can be increased when Norepinephrine is combined with Emepronium.]
[N06AX14, tianeptine, Tianeptine may increase the vasopressor activities of Norepinephrine.]
[C09AA02, enalapril, Norepinephrine may decrease the antihypertensive activities of Enalapril.]
[M01AG02, tolfenamic acid, The risk or severity of hypertension can be increased when Norepinephrine is combined with Tolfenamic acid.]
[N06AG03, toloxatone, Toloxatone may increase the hypertensive activities of Norepinephrine.]
[N06BA09, atomoxetine, Atomoxetine may increase the tachycardic activities of Norepinephrine.]
[C03CA04, torsemide, The risk or severity of hypokalemia can be increased when Norepinephrine is combined with Torasemide.]
[R01AA09, tramazoline, The therapeutic efficacy of Tramazoline can be increased when used in combination with Norepinephrine.]
[C09AA10, trandolapril, Norepinephrine may decrease the antihypertensive activities of Trandolapril.]
[A03AB08, tridihexethyl, The risk or severity of Tachycardia can be increased when Norepinephrine is combined with Tridihexethyl.]
[H02CA01, trilostane, The risk or severity of hypokalemia can be increased when Trilostane is combined with Norepinephrine.]
[R06AA10, trimethobenzamide, The therapeutic efficacy of Norepinephrine can be increased when used in combination with Trimethobenzamide.]
[G03GA05, follitropin alfa, The risk or severity of adverse effects can be increased when Norepinephrine is combined with Follitropin.]
[R06AX21, tritoqualine, The therapeutic efficacy of Norepinephrine can be increased when used in combination with Tritoqualine.]
[N04AA12, tropatepine, The risk or severity of Tachycardia can be increased when Norepinephrine is combined with Tropatepine.]
[R03CC11, tulobuterol, The risk or severity of hypertension can be increased when Norepinephrine is combined with Tulobuterol.]
[N01AB04, enflurane, Enflurane may increase the arrhythmogenic activities of Norepinephrine.]
[C02CA06, urapidil, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Urapidil.]
[S01FB02, ephedrine, The therapeutic efficacy of Ephedrine can be increased when used in combination with Norepinephrine.]
[N06AX16, venlafaxine, Venlafaxine may increase the tachycardic activities of Norepinephrine.]
[C01CX07, xamoterol, The risk or severity of hypertension can be increased when Norepinephrine is combined with Xamoterol.]
[S01GA03, xylometazoline, The risk or severity of hypertension can be increased when Norepinephrine is combined with Xylometazoline.]
[S01EA01, epinephrine, The therapeutic efficacy of Epinephrine can be increased when used in combination with Norepinephrine.]
[C09AA15, zofenopril, Norepinephrine may decrease the antihypertensive activities of Zofenopril.]
[M01AB04, zomepirac, The risk or severity of hypertension can be increased when Norepinephrine is combined with Zomepirac.]
[N03AX15, zonisamide, The risk or severity of Cardiac Arrhythmia can be increased when Norepinephrine is combined with Zonisamide.]
[C02AC02, guanfacine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Norepinephrine.]
[G02AB03, ergonovine, Ergometrine may increase the hypertensive and vasoconstricting activities of Norepinephrine.]
[C04AE01, ergoloid mesylates, USP, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Norepinephrine.]
[N02CA02, ergotamine, Ergotamine may increase the hypertensive and vasoconstricting activities of Norepinephrine.]
[G03CA03, estradiol, The serum concentration of Norepinephrine can be increased when it is combined with Estradiol.]
[R03BA09, fluticasone furoate, The risk or severity of hypokalemia can be increased when Fluticasone furoate is combined with Norepinephrine.]
[R03BA05, fluticasone, The risk or severity of hypokalemia can be increased when Fluticasone is combined with Norepinephrine.]
[C01CA15, gepefrine, The therapeutic efficacy of Gepefrine can be increased when used in combination with Norepinephrine.]
[N04AA05, profenamine, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Profenamine.]
[M01AC06, meloxicam, The risk or severity of hypertension can be increased when Norepinephrine is combined with Meloxicam.]
[C01CA01, etilefrine, The therapeutic efficacy of Etilefrine can be increased when used in combination with Norepinephrine.]
[N01AX07, etomidate, The risk or severity of hypertension can be increased when Etomidate is combined with Norepinephrine.]
[R06AX11, astemizole, The therapeutic efficacy of Norepinephrine can be increased when used in combination with Astemizole.]
[R06AX12, terfenadine, The therapeutic efficacy of Norepinephrine can be increased when used in combination with Terfenadine.]
[N06AX12, bupropion, The excretion of Norepinephrine can be decreased when combined with Bupropion.]
[A02BA03, famotidine, The serum concentration of Norepinephrine can be increased when it is combined with Famotidine.]
[C08CA02, felodipine, Norepinephrine may decrease the antihypertensive activities of Felodipine.]
[M01AE04, fenoprofen, The risk or severity of hypertension can be increased when Norepinephrine is combined with Fenoprofen.]
[R03CC04, fenoterol, The therapeutic efficacy of Fenoterol can be increased when used in combination with Norepinephrine.]
[N02AB03, fentanyl, The therapeutic efficacy of Fentanyl can be decreased when used in combination with Norepinephrine.]
[R03CC02, albuterol, The risk or severity of adverse effects can be increased when Norepinephrine is combined with Salbutamol.]
[L01BB06, clofarabine, The serum concentration of Clofarabine can be increased when it is combined with Norepinephrine.]
[G04BD02, flavoxate, The risk or severity of Tachycardia can be increased when Norepinephrine is combined with Flavoxate.]
[N02BG04, floctafenine, The risk or severity of hypertension can be increased when Norepinephrine is combined with Floctafenine.]
[H02AA02, fludrocortisone, The risk or severity of hypokalemia can be increased when Fludrocortisone is combined with Norepinephrine.]
[D07XB01, flumethasone, The risk or severity of hypokalemia can be increased when Flumethasone is combined with Norepinephrine.]
[D07AC08, fluocinonide, The risk or severity of hypokalemia can be increased when Fluocinonide is combined with Norepinephrine.]
[N06AA14, melitracen, Melitracen may increase the vasopressor activities of Norepinephrine.]
[H02AB03, fluocortolone, The risk or severity of hypokalemia can be increased when Fluocortolone is combined with Norepinephrine.]
[S01CB05, fluorometholone, The risk or severity of hypokalemia can be increased when Fluorometholone is combined with Norepinephrine.]
[N05AF01, flupenthixol, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Flupentixol.]
[N05CD01, flurazepam, The serum concentration of Norepinephrine can be increased when it is combined with Flurazepam.]
[S01BC04, flurbiprofen, The risk or severity of hypertension can be increased when Norepinephrine is combined with Flurbiprofen.]
[N06BX17, adrafinil, The risk or severity of hypertension can be increased when Norepinephrine is combined with Adrafinil.]
[G01AX06, furazolidone, Furazolidone may increase the hypertensive activities of Norepinephrine.]
[C03CA01, furosemide, The risk or severity of hypokalemia can be increased when Norepinephrine is combined with Furosemide.]
[S01AD09, ganciclovir, The risk or severity of adverse effects can be increased when Ganciclovir is combined with Norepinephrine.]
[N04BC06, cabergoline, Cabergoline may increase the hypertensive and vasoconstricting activities of Norepinephrine.]
[C01CA21, cafedrine, The risk or severity of adverse effects can be increased when Norepinephrine is combined with Cafedrine.]
[N01AH02, alfentanil, The risk or severity of hypertension can be increased when Norepinephrine is combined with Alfentanil.]
[A10BB01, glyburide, The therapeutic efficacy of Glyburide can be decreased when used in combination with Norepinephrine.]
[N05CM18, dexmedetomidine, The risk or severity of hypertension can be increased when Norepinephrine is combined with Dexmedetomidine.]
[C05AE01, nitroglycerin, Norepinephrine may decrease the antihypertensive activities of Nitroglycerin.]
[C01BD04, dofetilide, The serum concentration of Dofetilide can be increased when it is combined with Norepinephrine.]
[C02CA04, doxazosin, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Doxazosin.]
[H01AB01, thyrotropin alfa, The risk or severity of adverse effects can be increased when Norepinephrine is combined with Thyrotropin alfa.]
[C07AB09, esmolol, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Esmolol.]
[C09AA09, fosinopril, Norepinephrine may decrease the antihypertensive activities of Fosinopril.]
[S01EX01, guanethidine, Norepinephrine may decrease the antihypertensive activities of Guanethidine.]
[N01AB01, halothane, Halothane may increase the arrhythmogenic activities of Norepinephrine.]
[N05AH04, quetiapine, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Quetiapine.]
[C09CA01, losartan, Norepinephrine may decrease the antihypertensive activities of Losartan.]
[A07EC02, mesalamine, The risk or severity of hypertension can be increased when Mesalazine is combined with Norepinephrine.]
[R03CC05, hexoprenaline, The risk or severity of adverse effects can be increased when Norepinephrine is combined with Hexoprenaline.]
[J05AG01, nevirapine, The risk or severity of adverse effects can be increased when Nevirapine is combined with Norepinephrine.]
[C08CA10, nilvadipine, Norepinephrine may decrease the antihypertensive activities of Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of hypertension can be increased when Norepinephrine is combined with Nimesulide.]
[R06AE06, oxatomide, The therapeutic efficacy of Norepinephrine can be increased when used in combination with Oxatomide.]
[C09AA04, perindopril, Norepinephrine may decrease the antihypertensive activities of Perindopril.]
[C02DB02, hydralazine, Norepinephrine may decrease the antihypertensive activities of Hydralazine.]
[C03AA03, hydrochlorothiazide, The risk or severity of hypokalemia can be increased when Norepinephrine is combined with Hydrochlorothiazide.]
[S02BA01, hydrocortisone, The risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Norepinephrine.]
[D07AB02, hydrocortisone butyrate, The risk or severity of hypokalemia can be increased when Hydrocortisone butyrate is combined with Norepinephrine.]
[C03AA02, hydroflumethiazide, The risk or severity of hypokalemia can be increased when Norepinephrine is combined with Hydroflumethiazide.]
[A12BA02, potassium citrate, The risk or severity of Cardiac Arrhythmia can be increased when Norepinephrine is combined with Potassium citrate.]
[G04BD06, propiverine, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Propiverine.]
[C02AC06, rilmenidine, Norepinephrine may decrease the antihypertensive activities of Rilmenidine.]
[R02AX02, ibuprofen, The risk or severity of hypertension can be increased when Norepinephrine is combined with Ibuprofen.]
[N01AH03, sufentanil, The risk or severity of hypertension can be increased when Norepinephrine is combined with Sufentanil.]
[N06AA02, imipramine, Imipramine may increase the vasopressor activities of Norepinephrine.]
[R01AD07, tixocortol, The risk or severity of hypokalemia can be increased when Tixocortol is combined with Norepinephrine.]
[M03BX02, tizanidine, The risk or severity of adverse effects can be increased when Tizanidine is combined with Norepinephrine.]
[C03BA11, indapamide, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Indapamide.]
[S01BC01, indomethacin, The risk or severity of hypertension can be increased when Indomethacin is combined with Norepinephrine.]
[C02CA02, indoramin, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Indoramin.]
[N06AX17, milnacipran, Milnacipran may increase the tachycardic activities of Norepinephrine.]
[A03AA30, piperidolate, The risk or severity of Tachycardia can be increased when Norepinephrine is combined with Piperidolate.]
[S01XA28, varenicline, The excretion of Varenicline can be decreased when combined with Norepinephrine.]
[R06AE01, buclizine, The therapeutic efficacy of Norepinephrine can be increased when used in combination with Buclizine.]
[G02CX01, atosiban, The risk or severity of adverse effects can be increased when Norepinephrine is combined with Atosiban.]
[L01XX35, anagrelide, The risk or severity of Tachycardia can be increased when Anagrelide is combined with Norepinephrine.]
[C07AA01, alprenolol, Alprenolol may decrease the bronchodilatory activities of Norepinephrine.]
[C03BA02, quinethazone, The risk or severity of Cardiac Arrhythmia can be increased when Norepinephrine is combined with Quinethazone.]
[N06AA13, iprindole, Iprindole may increase the vasopressor activities of Norepinephrine.]
[N06AF05, iproniazid, Iproniazid may increase the hypertensive activities of Norepinephrine.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the hypertensive activities of Norepinephrine.]
[R03CC06, isoetharine, The risk or severity of adverse effects can be increased when Isoetharine is combined with Norepinephrine.]
[C09AA16, imidapril, Norepinephrine may decrease the antihypertensive activities of Imidapril.]
[N01AB06, isoflurane, Isoflurane may increase the arrhythmogenic activities of Norepinephrine.]
[N04BX02, entacapone, The metabolism of Norepinephrine can be decreased when combined with Entacapone.]
[R03CB01, isoproterenol, The therapeutic efficacy of Isoprenaline can be increased when used in combination with Norepinephrine.]
[C04AA01, isoxsuprine, The therapeutic efficacy of Isoxsuprine can be increased when used in combination with Norepinephrine.]
[N01AX03, ketamine, The risk or severity of Tachycardia can be increased when Norepinephrine is combined with Ketamine.]
[C02KD01, ketanserin, Norepinephrine may decrease the antihypertensive activities of Ketanserin.]
[H02CA04, levoketoconazole, The serum concentration of Norepinephrine can be increased when it is combined with Levoketoconazole.]
[N05AH03, olanzapine, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Olanzapine.]
[M02AA10, ketoprofen, The risk or severity of hypertension can be increased when Norepinephrine is combined with Ketoprofen.]
[R06AX25, mizolastine, The therapeutic efficacy of Norepinephrine can be increased when used in combination with Mizolastine.]
[S01GX08, ketotifen, The therapeutic efficacy of Norepinephrine can be increased when used in combination with Ketotifen.]
[C01CA22, arbutamine, The risk or severity of adverse effects can be increased when Norepinephrine is combined with Arbutamine.]
[N04BC09, rotigotine, The risk or severity of hypertension can be increased when Norepinephrine is combined with Rotigotine.]
[M01AE11, tiaprofenic acid, The risk or severity of hypertension can be increased when Norepinephrine is combined with Tiaprofenic acid.]
[C07AG01, labetalol, The therapeutic efficacy of Labetalol can be increased when used in combination with Norepinephrine.]
[N04BB01, amantadine, The serum concentration of Amantadine can be increased when it is combined with Norepinephrine.]
[C02AA05, deserpidine, Norepinephrine may decrease the antihypertensive activities of Deserpidine.]
[C03CC01, ethacrynic acid, The risk or severity of hypokalemia can be increased when Norepinephrine is combined with Etacrynic acid.]
[S02DA01, lidocaine, The risk or severity of hypertension can be increased when Norepinephrine is combined with Lidocaine.]
[C03DB01, amiloride, The serum concentration of Norepinephrine can be increased when it is combined with Amiloride.]
[N02CA07, lisuride, Lisuride may increase the hypertensive and vasoconstricting activities of Norepinephrine.]
[N06AA07, lofepramine, Lofepramine may increase the vasopressor activities of Norepinephrine.]
[V04CX04, mannitol, The risk or severity of Cardiac Arrhythmia can be increased when Norepinephrine is combined with Mannitol.]
[N06AA21, maprotiline, The risk or severity of Tachycardia can be increased when Norepinephrine is combined with Maprotiline.]
[A08AA05, mazindol, The risk or severity of adverse effects can be increased when Mazindol is combined with Norepinephrine.]
[C02BB01, mecamylamine, Norepinephrine may decrease the antihypertensive activities of Mecamylamine.]
[R06AE05, meclizine, The therapeutic efficacy of Norepinephrine can be increased when used in combination with Meclizine.]
[M02AA18, meclofenamic acid, The risk or severity of hypertension can be increased when Norepinephrine is combined with Meclofenamic acid.]
[C01AA08, medigoxin, The risk or severity of Cardiac Arrhythmia can be increased when Norepinephrine is combined with Metildigoxin.]
[C03BA05, mefruside, The risk or severity of Cardiac Arrhythmia can be increased when Norepinephrine is combined with Mefruside.]
[N06DX01, memantine, The serum concentration of Memantine can be increased when it is combined with Norepinephrine.]
[C01CA11, mephentermine, The therapeutic efficacy of Mephentermine can be increased when used in combination with Norepinephrine.]
[C03BC01, mersalyl, The risk or severity of Cardiac Arrhythmia can be increased when Norepinephrine is combined with Mersalyl.]
[N05AX13, paliperidone, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Paliperidone.]
[C01CA09, metaraminol, The therapeutic efficacy of Metaraminol can be increased when used in combination with Norepinephrine.]
[A10BA02, metformin, The serum concentration of Norepinephrine can be increased when it is combined with Metformin.]
[N06BA03, methamphetamine, The therapeutic efficacy of Metamfetamine can be increased when used in combination with Norepinephrine.]
[A03AB07, methantheline, The risk or severity of Tachycardia can be increased when Norepinephrine is combined with Methantheline.]
[R06AC05, methapyrilene, The therapeutic efficacy of Norepinephrine can be increased when used in combination with Methapyrilene.]
[J05AF05, lamivudine, The serum concentration of Lamivudine can be increased when it is combined with Norepinephrine.]
[S01EC05, methazolamide, The risk or severity of Cardiac Arrhythmia can be increased when Norepinephrine is combined with Methazolamide.]
[G02CB05, metergoline, Metergoline may increase the hypertensive and vasoconstricting activities of Norepinephrine.]
[H03BB02, methimazole, The risk or severity of adverse effects can be increased when Norepinephrine is combined with Methimazole.]
[N05AA02, methotrimeprazine, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Methotrimeprazine.]
[C01CA10, methoxamine, The therapeutic efficacy of Methoxamine can be increased when used in combination with Norepinephrine.]
[N02BG09, methoxyflurane, Methoxyflurane may increase the arrhythmogenic activities of Norepinephrine.]
[C03AA08, methyclothiazide, The risk or severity of hypokalemia can be increased when Norepinephrine is combined with Methyclothiazide.]
[C02AB01, methyldopa, Norepinephrine may decrease the antihypertensive activities of Methyldopa.]
[V04CG05, methylene blue, Methylene blue may increase the hypertensive activities of Norepinephrine.]
[G02AB01, methylergonovine, Methylergometrine may increase the hypertensive and vasoconstricting activities of Norepinephrine.]
[R03DA05, aminophylline, The risk or severity of adverse effects can be increased when Norepinephrine is combined with Aminophylline.]
[N06BA04, methylphenidate, The risk or severity of hypertension can be increased when Norepinephrine is combined with Methylphenidate.]
[H02AB04, methylprednisolone, The risk or severity of hypokalemia can be increased when Methylprednisolone is combined with Norepinephrine.]
[D07AC14, methylprednisolone aceponate, The risk or severity of hypokalemia can be increased when Methylprednisolone aceponate is combined with Norepinephrine.]
[N02CA04, methysergide, Methysergide may increase the hypertensive and vasoconstricting activities of Norepinephrine.]
[C03BA08, metolazone, The risk or severity of Cardiac Arrhythmia can be increased when Norepinephrine is combined with Metolazone.]
[C07AB02, metoprolol, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Metoprolol.]
[N06AX03, mianserin, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Mianserin.]
[N02BB03, aminopyrine, The risk or severity of hypertension can be increased when Norepinephrine is combined with Aminophenazone.]
[C01CA17, midodrine, The therapeutic efficacy of Midodrine can be increased when used in combination with Norepinephrine.]
[C09CA03, valsartan, Norepinephrine may decrease the antihypertensive activities of Valsartan.]
[D11AX01, minoxidil, Norepinephrine may decrease the antihypertensive activities of Minoxidil.]
[N06BA12, lisdexamfetamine, The therapeutic efficacy of Lisdexamfetamine can be increased when used in combination with Norepinephrine.]
[C01BD01, amiodarone, The serum concentration of Norepinephrine can be increased when it is combined with Amiodarone.]
[N06AA09, amitriptyline, Amitriptyline may increase the vasopressor activities of Norepinephrine.]
[G04CA04, silodosin, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Silodosin.]
[R03BB01, ipratropium bromide, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Norepinephrine.]
[N06AA17, amoxapine, Amoxapine may increase the vasopressor activities of Norepinephrine.]
[C07AA12, nadolol, Nadolol may decrease the bronchodilatory activities of Norepinephrine.]
[S01GA01, naphazoline, The therapeutic efficacy of Naphazoline can be increased when used in combination with Norepinephrine.]
[N06BA01, amphetamine, The therapeutic efficacy of Amphetamine can be increased when used in combination with Norepinephrine.]
[M02AA12, naproxen, The risk or severity of hypertension can be increased when Norepinephrine is combined with Naproxen.]
[N06AX21, duloxetine, Duloxetine may increase the tachycardic activities of Norepinephrine.]
[N04BX01, tolcapone, The metabolism of Norepinephrine can be decreased when combined with Tolcapone.]
[N01AH06, remifentanil, The risk or severity of hypertension can be increased when Norepinephrine is combined with Remifentanil.]
[N05AX14, iloperidone, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Iloperidone.]
[N06AX23, desvenlafaxine, Desvenlafaxine may increase the tachycardic activities of Norepinephrine.]
[C09CA07, telmisartan, Norepinephrine may decrease the antihypertensive activities of Telmisartan.]
[N06AF02, nialamide, Nialamide may increase the hypertensive activities of Norepinephrine.]
[C08CA04, nicardipine, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Nicardipine.]
[C04AE02, nicergoline, Nicergoline may increase the hypertensive and vasoconstricting activities of Norepinephrine.]
[N07BA01, nicotine, The serum concentration of Norepinephrine can be increased when it is combined with Nicotine.]
[M02AA17, niflumic acid, The risk or severity of hypertension can be increased when Norepinephrine is combined with Niflumic acid.]
[C08CA06, nimodipine, Norepinephrine may decrease the antihypertensive activities of Nimodipine.]
[C08CA07, nisoldipine, Norepinephrine may decrease the antihypertensive activities of Nisoldipine.]
[C08CA08, nitrendipine, Norepinephrine may decrease the antihypertensive activities of Nitrendipine.]
[N04BC05, pramipexole, The serum concentration of Pramipexole can be increased when it is combined with Norepinephrine.]
[C02DD01, nitroprusside, Norepinephrine may decrease the antihypertensive activities of Nitroprusside.]
[N01AX13, nitrous oxide, Nitrous oxide may increase the arrhythmogenic activities of Norepinephrine.]
[C02KX01, bosentan, Norepinephrine may decrease the antihypertensive activities of Bosentan.]
[N06AA10, nortriptyline, Nortriptyline may increase the vasopressor activities of Norepinephrine.]
[G02CA02, nylidrin, The therapeutic efficacy of Nylidrin can be increased when used in combination with Norepinephrine.]
[N06AA05, opipramol, Opipramol may increase the vasopressor activities of Norepinephrine.]
[R03CB03, metaproterenol, The therapeutic efficacy of Orciprenaline can be increased when used in combination with Norepinephrine.]
[G04CA02, tamsulosin, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Tamsulosin.]
[C01AC01, ouabain, The risk or severity of Cardiac Arrhythmia can be increased when Norepinephrine is combined with Ouabain.]
[C07AA02, oxprenolol, Oxprenolol may decrease the bronchodilatory activities of Norepinephrine.]
[C01DX03, oxyfedrine, The risk or severity of hypertension can be increased when Norepinephrine is combined with Oxyfedrine.]
[S01GA04, oxymetazoline, Norepinephrine may increase the hypertensive and vasoconstricting activities of Oxymetazoline.]
[S01BC02, oxyphenbutazone, The risk or severity of hypertension can be increased when Norepinephrine is combined with Oxyphenbutazone.]
[A03AB03, oxyphenonium, The risk or severity of Tachycardia can be increased when Oxyphenonium is combined with Norepinephrine.]
[H01BB02, oxytocin, The risk or severity of hypertension can be increased when Norepinephrine is combined with Oxytocin.]
[V04CH30, 4-aminohippuric acid, The serum concentration of Norepinephrine can be increased when it is combined with Aminohippuric acid.]
[N05AH05, asenapine, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Asenapine.]
[M03AC01, pancuronium, The risk or severity of adverse effects can be increased when Pancuronium is combined with Norepinephrine.]
[H02AB05, paramethasone, The risk or severity of hypokalemia can be increased when Paramethasone is combined with Norepinephrine.]
[C02KC01, pargyline, Pargyline may increase the hypertensive activities of Norepinephrine.]
[G04BD11, fesoterodine, The risk or severity of Tachycardia can be increased when Norepinephrine is combined with Fesoterodine.]
[C07AA23, penbutolol, Penbutolol may decrease the bronchodilatory activities of Norepinephrine.]
[C04AD03, pentoxifylline, The risk or severity of adverse effects can be increased when Norepinephrine is combined with Pentoxifylline.]
[N04BC02, pergolide, Pergolide may increase the hypertensive and vasoconstricting activities of Norepinephrine.]
[N06AF03, phenelzine, Phenelzine may increase the hypertensive activities of Norepinephrine.]
[A10BA01, phenformin, The serum concentration of Norepinephrine can be increased when it is combined with Phenformin.]
[R06AB05, pheniramine, The therapeutic efficacy of Norepinephrine can be increased when used in combination with Pheniramine.]
[C04AX02, phenoxybenzamine, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Phenoxybenzamine.]
[A08AA01, phentermine, The therapeutic efficacy of Phentermine can be increased when used in combination with Norepinephrine.]
[V03AB36, phentolamine, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Phentolamine.]
[M02AA01, phenylbutazone, The risk or severity of hypertension can be increased when Norepinephrine is combined with Phenylbutazone.]
[S01GA05, phenylephrine, The therapeutic efficacy of Phenylephrine can be increased when used in combination with Norepinephrine.]
[R01BA01, phenylpropanolamine, The therapeutic efficacy of Phenylpropanolamine can be increased when used in combination with Norepinephrine.]
[C08CX01, mibefradil, Norepinephrine may decrease the antihypertensive activities of Mibefradil.]
[C07AA03, pindolol, Pindolol may decrease the bronchodilatory activities of Norepinephrine.]
[J05AE01, saquinavir, The risk or severity of adverse effects can be increased when Saquinavir is combined with Norepinephrine.]
[C09CA02, eprosartan, Norepinephrine may decrease the antihypertensive activities of Eprosartan.]
[A02BX03, pirenzepine, The risk or severity of Tachycardia can be increased when Norepinephrine is combined with Pirenzepine.]
[S01BC06, piroxicam, The risk or severity of hypertension can be increased when Norepinephrine is combined with Piroxicam.]
[J01MA11, grepafloxacin, The serum concentration of Norepinephrine can be increased when it is combined with Grepafloxacin.]
[N02CX01, pizotyline, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Pizotifen.]
[C09CA04, irbesartan, Norepinephrine may decrease the antihypertensive activities of Irbesartan.]
[C03AA05, polythiazide, The risk or severity of hypokalemia can be increased when Norepinephrine is combined with Polythiazide.]
[V03AB21, potassium iodide, The risk or severity of adverse effects can be increased when Norepinephrine is combined with Potassium Iodide.]
[C07AB01, practolol, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Practolol.]
[C02CA01, prazosin, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Prazosin.]
[S03BA02, prednisolone, The risk or severity of hypokalemia can be increased when Prednisolone is combined with Norepinephrine.]
[H02AB07, prednisone, The risk or severity of hypokalemia can be increased when Prednisone is combined with Norepinephrine.]
[R06AX05, antazoline, The therapeutic efficacy of Norepinephrine can be increased when used in combination with Antazoline.]
[M04AB01, probenecid, The serum concentration of Norepinephrine can be increased when it is combined with Probenecid.]
[C01BA02, procainamide, The serum concentration of Procainamide can be increased when it is combined with Norepinephrine.]
[S01HA05, procaine, Procaine may increase the hypertensive activities of Norepinephrine.]
[L01XB01, procarbazine, Procarbazine may increase the hypertensive activities of Norepinephrine.]
[N04AA04, procyclidine, The risk or severity of Tachycardia can be increased when Norepinephrine is combined with Procyclidine.]
[G03DA04, progesterone, The serum concentration of Norepinephrine can be increased when it is combined with Progesterone.]
[N05AA03, promazine, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Promazine.]
[R06AD02, promethazine, The therapeutic efficacy of Norepinephrine can be increased when used in combination with Promethazine.]
[C01BC03, propafenone, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Propafenone.]
[A03AB05, propantheline, The risk or severity of Tachycardia can be increased when Norepinephrine is combined with Propantheline.]
[R06AX26, fexofenadine, The therapeutic efficacy of Norepinephrine can be increased when used in combination with Fexofenadine.]
[N05AC01, periciazine, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Periciazine.]
[N05CM06, propiomazine, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Propiomazine.]
[N01AX10, propofol, The risk or severity of hypertension can be increased when Norepinephrine is combined with Propofol.]
[C07AA05, propranolol, Propranolol may decrease the bronchodilatory activities of Norepinephrine.]
[H03BA02, propylthiouracil, The risk or severity of adverse effects can be increased when Norepinephrine is combined with Propylthiouracil.]
[C01AB01, proscillaridin, The risk or severity of Cardiac Arrhythmia can be increased when Norepinephrine is combined with Proscillaridin.]
[N02CC04, rizatriptan, The risk or severity of hypertension can be increased when Norepinephrine is combined with Rizatriptan.]
[B01AC09, epoprostenol, Norepinephrine may decrease the antihypertensive activities of Epoprostenol.]
[N06AA11, protriptyline, Protriptyline may increase the vasopressor activities of Norepinephrine.]
[R01BA02, pseudoephedrine, The therapeutic efficacy of Pseudoephedrine can be increased when used in combination with Norepinephrine.]
[N05AX12, aripiprazole, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Aripiprazole.]
[N07XX07, dalfampridine, The serum concentration of Dalfampridine can be increased when it is combined with Norepinephrine.]
[A03AB15, diphemanil, The risk or severity of Tachycardia can be increased when Norepinephrine is combined with Diphemanil.]
[A03AB09, isopropamide, The risk or severity of Tachycardia can be increased when Norepinephrine is combined with Isopropamide.]
[S01FA03, methscopolamine, The risk or severity of Tachycardia can be increased when Norepinephrine is combined with Methscopolamine.]
[R06AC01, pyrilamine, The therapeutic efficacy of Norepinephrine can be increased when used in combination with Mepyramine.]
[P01AX05, quinacrine, The serum concentration of Norepinephrine can be increased when it is combined with Quinacrine.]
[C01BA01, quinidine, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Quinidine.]
[P01BC01, quinine, The serum concentration of Norepinephrine can be increased when it is combined with Quinine.]
[A02BA02, ranitidine, The serum concentration of Ranitidine can be increased when it is combined with Norepinephrine.]
[C02AA01, rescinnamine, Norepinephrine may decrease the antihypertensive activities of Rescinnamine.]
[C02AA02, reserpine, The serum concentration of Reserpine can be increased when it is combined with Norepinephrine.]
[R03AC05, rimiterol, The risk or severity of hypertension can be increased when Norepinephrine is combined with Rimiterol.]
[G02CA01, ritodrine, The therapeutic efficacy of Ritodrine can be increased when used in combination with Norepinephrine.]
[N02BA05, salicylamide, The risk or severity of hypertension can be increased when Norepinephrine is combined with Salicylamide.]
[A07EC01, sulfasalazine, The risk or severity of hypertension can be increased when Norepinephrine is combined with Sulfasalazine.]
[S01BC08, salicylic acid, The risk or severity of hypertension can be increased when Norepinephrine is combined with Salicylic acid.]
[S01FA02, scopolamine, The risk or severity of Tachycardia can be increased when Norepinephrine is combined with Scopolamine.]
[N04BD01, selegiline, Selegiline may increase the hypertensive activities of Norepinephrine.]
[C07AA07, sotalol, Sotalol may decrease the bronchodilatory activities of Norepinephrine.]
[C03DA01, spironolactone, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Spironolactone.]
